N-cyclopropyl-4-ethylbenzenesulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-cyclopropyl-4-ethylbenzenesulfonamide
• 化学式: C₁₁H₁₅NO₂S
• mdl: MFCD03550605
• 分子量: 225.31
• InChiKey: KDQVXDFDODVWJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS
  申请人：Mc Allister Andrès

  公开号：US20130143895A1

  公开（公告）日：2013-06-06

  The present invention relates to substituted aromatic bicyclic compounds containing pyrimidine and pyridine rings of formula (I) having the structure as well as pharmaceutically acceptable salts thereof. The compounds of the present invention are useful as tyrosine kinase inhibitors, preferably SRC family kinases (SFKs) inhibitors, in particular as multi SFK/JAK. kinases inhibitors and even preferably as dual c-SRC/JAK kinases inhibitors, thereby inhibiting the STAT3 activation and therefore abnormal growth of particular cell types. Notably, the compounds of the present invention are useful for the treatment or inhibition of certain diseases that are the result of deregulation of STAT3.

  本发明涉及公式（I）的含有嘧啶和吡啶环的取代芳香族双环化合物及其药学上可接受的盐。本发明的化合物可用作酪氨酸激酶抑制剂，优选为SRC家族激酶（SFKs）抑制剂，特别是作为多种SFK/JAK激酶抑制剂，更优选作为双重c-SRC/JAK激酶抑制剂，从而抑制STAT3的活化，因此抑制特定细胞类型的异常生长。值得注意的是，本发明的化合物可用于治疗或抑制由STAT3失调引起的某些疾病。
• Compounds and Methods for Kinase Modulation, and Indications Therefor
  申请人：Ibrahim Prabha N.

  公开号：US20100286142A1

  公开（公告）日：2010-11-11

  Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, and forms thereof are active on each of BRaf and c-Raf-1 protein kinase, and may also be active on either or both of A-Raf and B-Raf V600E protein kinase. Also described are methods of use thereof to treat diseases and conditions, including melanoma, colorectal cancer, thyroid cancer, ovarian cancer, and biliary tract cancer.

  本文描述了化合物及其盐、配方、共轭物、衍生物、形式和用途。在某些方面和实施例中，所述化合物或其盐、配方、共轭物、衍生物和形式对BRaf和c-Raf-1蛋白激酶都具有活性，并且还可能对A-Raf和B-Raf V600E蛋白激酶中的任何一个或两个都具有活性。还描述了使用它们治疗疾病和病况的方法，包括黑色素瘤、结肠直肠癌、甲状腺癌、卵巢癌和胆道癌。
• US8198273B2
  申请人：——

  公开号：US8198273B2

  公开（公告）日：2012-06-12
• US8962637B2
  申请人：——

  公开号：US8962637B2

  公开（公告）日：2015-02-24
• [EN] SULFONAMIDE DERIVATIVES<br/>[FR] DERIVES SULFONAMIDE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2006005486A1

  公开（公告）日：2006-01-19

  The invention relates to compounds of the general formula (I), wherein R1-R5 and R2’-R4’ are as described in the claims and to pharmaceutically suitable acid additon salts, optical pure enantiomers, racemates or diastereomeric mixtures thereof for the treatment of Alzheimer’s disease or common cancers.